| Autor: |
Lorena Incorvaia, Alessandra Dimino, Laura Algeri, Chiara Brando, Luigi Magrin, Ida De Luca, Erika Pedone, Alessandro Perez, Roberta Sciacchitano, Annalisa Bonasera, Tancredi Didier Bazan Russo, Federica Li Pomi, Marta Peri, Valerio Gristina, Antonio Galvano, Dario Giuffrida, Ivan Fazio, Francesca Toia, Adriana Cordova, Ada Maria Florena, Antonio Giordano, Viviana Bazan, Antonio Russo, Giuseppe Badalamenti |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Frontiers in Oncology, Vol 13 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2234-943X |
| DOI: |
10.3389/fonc.2023.1141500 |
| Popis: |
BackgroundMerkel cell carcinoma (MCC) is a rare and aggressive skin cancer, associated with a worse prognosis. The Immune Checkpoint Inhibitors (ICIs) avelumab and pembrolizumab have been recently approved as first-line treatment in metastatic MCC (mMCC). The clinical observation of improved outcomes in obese patients following treatment with ICIs, known as the “obesity paradox”, has been studied across many types of tumors. Probably due to the rarity of this tumor, data on mMMC patients are lacking.Patients and methodsThis is an observational, hospital-based, study to investigate the role of Body Mass Index (BMI) as predictive biomarker of ICI response in mMCC patients treated with avelumab as first-line treatment. The study population included the patients treated from February 2019 to October 2022 in an Italian referral center for rare tumors. Clinico-pathological characteristics, BMI, laboratory parameters (NLR and platelet count), and response to avelumab were analyzed from a MCC System database prospectively collected.ResultsThirty-two (32) patients were included. Notably, the presence of pre-treatment BMI ≥ 30 was significantly associated with longer PFS [BMI < 30 Group: median PFS, 4 months (95% CI: 2.5-5.4); BMI ≥ 30 Group: median PFS, not reached; p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
